This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down
by Zacks Equity Research
REGN reports lower-than-expected Q1 results. Lead drug Eylea sales plunge in the United States due to competition. Stock down.
AZN Q1 Earnings Beat, Stock Down on Soft Sales Performance of Key Drugs
by Zacks Equity Research
AstraZeneca reports mixed first-quarter 2025 results. The fall in pre-market is likely due to the soft sales performance of key drugs across the oncology and rare disease segments.
Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth
by Zacks Equity Research
SNY beats Q1 estimates for earnings, while missing the same for sales. It expects earnings growth to rebound in 2025.
Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & More
by Ekta Bagri
BMY and REGN are in the spotlight this week following study data and regulatory updates, respectively.
The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi
by Zacks Equity Research
Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi are part of the Zacks top Analyst Blog.
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?
by Ahan Chakraborty
Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.
Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria
by Zacks Equity Research
The FDA approves SNY and REGN's Dupixent for treating chronic spontaneous urticaria, marking the seventh approved indication of the drug.
Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings?
by Zacks Equity Research
AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, are expected to have driven the company's top line.
Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback
by Kinjel Shah
JNJ beats first-quarter estimates for earnings and sales. PFE ends the development of the weight loss pill danuglipron.
Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications
by Zacks Equity Research
SNY shares preliminary data from phase II study on amlitelimab in moderate-to-severe asthma. It also provides updates on lunsekimig and itepekimab studies.
Why You Shouldn't Bet Against Sanofi (SNY) Stock
by Zacks Equity Research
Sanofi (SNY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure
by Kinjel Shah
FDA approves SNY's hemophilia therapy, fitusiran, and NVS' rare kidney disease drug, Vanrafia.
SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases
by Zacks Equity Research
The FDA bestows an orphan drug designation to Sanofi's rilzabrutinib for treating warm autoimmune hemolytic anemia and IgG4-related disease.
NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program
by Zacks Equity Research
Nurix stock gains as SNY expands its partnership, licensing a research program targeting a previously untreatable transcription factor for autoimmune diseases.
SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States
by Zacks Equity Research
The FDA approves Sanofi's Qfitlia as the first therapy in the United States to treat hemophilia A or B with or without inhibitors.
Is First Trust Value Line Dividend ETF (FVD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FVD
Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive
by Zacks Equity Research
The European Commission approves MRK's pneumococcal 21-valent conjugate vaccine, Capvaxive, for pneumococcal vaccination in adults.
Sanofi's Chlamydia Vaccine Candidate Gets FDA's Fast Track Tag
by Zacks Equity Research
The FDA bestows a fast-track designation to SNY's mRNA vaccine candidate for the prevention of chlamydia infection.
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)
by Zacks Equity Research
If approved, SNY's tolebrutinib will be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in multiple sclerosis.
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib
by Zacks Equity Research
If approved, SNY's tolebrutinib will be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in multiple sclerosis.
Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals
by Kinjel Shah
Pfizer sells 7.3% remaining stake in Haleon. FDA approves the expanded use of JNJ and NVS drugs.
Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease Drug
by Zacks Equity Research
Through the Dren Bio deal, SNY intends to expand its immunology pipeline and establish itself as a leading immunology company.
AMGN's Eczema Drug Meets Goal in Two Late-Stage Studies
by Zacks Equity Research
Data from two more late-stage studies show that treatment with Amgen's rocatinlimab improves outcomes in atopic dermatitis indication.
Pfizer (PFE) Down 1.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cytokinetics Q4 Loss Wider Than Expected, Aficamten in Focus
by Zacks Equity Research
CYTK reports a wider-than-expected Q4 loss as operating expenses increase. CYTK is gearing up to launch lead candidate aficamten upon a potential FDA approval.